Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL NCT05210270

HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy (HYACINCT)

Phase 1/2 Trial Evaluating the Effectiveness and Safety of Dose-adapted HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy

Sponsor: Philippine Council for Health Research & Development

Conditions Locally Advanced Cervical Carcinoma

Interventions Hypofractionation

Updated 5 times since 2022 Last updated: Jan 28, 2023 Started: Jan 31, 2024 Primary completion: Mar 31, 2028 Completion: Mar 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05210270, this PHASE1/PHASE2 trial focuses on Locally Advanced Cervical Carcinoma and remains actively recruiting participants. Sponsored by Philippine Council for Health Research & Development, it has been updated 5 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Feb 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Jul 2022 — Feb 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2
Feb 2022 — Jul 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Philippine Council for Health Research & Development
University of Santo Tomas Hospital, Philippines

Data source: University of Santo Tomas Hospital, Philippines

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.